{
  "metadata": {
    "timestamp": "2025-11-26T13:17:21.653507",
    "genes": [
      "ADAM28",
      "LINC02615",
      "POT1-AS1",
      "MET",
      "HILPDA",
      "LUCAT1",
      "PTGS2",
      "RUNX2",
      "SPNS2",
      "PHLDB2",
      "LINC01705",
      "FAM160A1",
      "ERRFI1",
      "FAT4",
      "TNNI3K",
      "TRIB3",
      "NDRG1",
      "AC051619.5",
      "AC083837.1",
      "PRKCH",
      "PPP1R3C",
      "MGAM",
      "ANGPTL4",
      "COL13A1",
      "CHSY3",
      "AP001528.1",
      "CDON",
      "CAV1",
      "SHISA6",
      "SLC39A14",
      "C21orf62-AS1",
      "HMOX1",
      "BNIP3L",
      "LINC01376",
      "ABI3BP",
      "VLDLR-AS1",
      "OLFM1",
      "LTBP2",
      "AHNAK2",
      "NOX4",
      "AC092944.1",
      "COL5A1",
      "PLAG1",
      "GCNT1",
      "AC099681.1",
      "CFAP61",
      "RPL34-AS1",
      "OSMR-AS1",
      "AMPD3",
      "EHHADH",
      "COL24A1",
      "RNF217-AS1",
      "AP006545.3",
      "EPHA1-AS1",
      "EPHA3",
      "ZNF385B",
      "LINC02340",
      "LVRN",
      "PDE4C",
      "GPC5",
      "RCAN2",
      "EPSTI1",
      "AC008014.1",
      "LINC00240",
      "AL158064.1",
      "AL390957.1",
      "MX2",
      "C4orf47",
      "ABLIM3",
      "ITGB3",
      "SCN9A",
      "C9orf153",
      "SLC6A6",
      "NECTIN3-AS1",
      "CALN1",
      "GRK5",
      "CPEB1",
      "CPA4",
      "UNC5C"
    ],
    "context": "malignant glioblastoma cells",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "cached": false,
    "project": "glioblastoma_ds_auto",
    "query": "8_Gliosis_hypoxia",
    "source": "reorganization_script",
    "provider_config": {
      "timeout": 600,
      "max_retries": 3,
      "parameters": {
        "allowed_domains": [],
        "reasoning_effort": "medium",
        "search_domain_filter": [],
        "return_citations": true,
        "temperature": 0.0
      }
    },
    "citation_count": 59
  },
  "raw_response": {
    "markdown": "## Question\n\nPerform comprehensive literature analysis for the following gene list in the specified biological context.\n\n**Gene List**: [\"ADAM28\", \"LINC02615\", \"POT1-AS1\", \"MET\", \"HILPDA\", \"LUCAT1\", \"PTGS2\", \"RUNX2\", \"SPNS2\", \"PHLDB2\", \"LINC01705\", \"FAM160A1\", \"ERRFI1\", \"FAT4\", \"TNNI3K\", \"TRIB3\", \"NDRG1\", \"AC051619.5\", \"AC083837.1\", \"PRKCH\", \"PPP1R3C\", \"MGAM\", \"ANGPTL4\", \"COL13A1\", \"CHSY3\", \"AP001528.1\", \"CDON\", \"CAV1\", \"SHISA6\", \"SLC39A14\", \"C21orf62-AS1\", \"HMOX1\", \"BNIP3L\", \"LINC01376\", \"ABI3BP\", \"VLDLR-AS1\", \"OLFM1\", \"LTBP2\", \"AHNAK2\", \"NOX4\", \"AC092944.1\", \"COL5A1\", \"PLAG1\", \"GCNT1\", \"AC099681.1\", \"CFAP61\", \"RPL34-AS1\", \"OSMR-AS1\", \"AMPD3\", \"EHHADH\", \"COL24A1\", \"RNF217-AS1\", \"AP006545.3\", \"EPHA1-AS1\", \"EPHA3\", \"ZNF385B\", \"LINC02340\", \"LVRN\", \"PDE4C\", \"GPC5\", \"RCAN2\", \"EPSTI1\", \"AC008014.1\", \"LINC00240\", \"AL158064.1\", \"AL390957.1\", \"MX2\", \"C4orf47\", \"ABLIM3\", \"ITGB3\", \"SCN9A\", \"C9orf153\", \"SLC6A6\", \"NECTIN3-AS1\", \"CALN1\", \"GRK5\", \"CPEB1\", \"CPA4\", \"UNC5C\"]\n\n**Biological Context**: malignant glioblastoma cells\n\n**Analysis Strategy**:\n1. Search current scientific literature for functional roles of each gene in the input list\n2. Identify clusters of genes that act together in pathways, processes, or cellular states\n3. Treat each cluster as a potential gene program within the list\n4. Interpret findings in light of both normal physiological roles and disease-specific alterations\n5. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant.\n\n**Guidelines**:\n* Anchor all predictions in either the normal physiology and development of the cell type and tissue specified in the context OR the alterations and dysregulations characteristic of the specified disease\n* Connect gene-level roles to program-level implications\n* Consider gene interactions, regulatory networks, and pathway dynamics\n* Highlight cases where multiple genes collectively strengthen evidence\n* Ensure all claims are backed by experimental evidence with proper attribution\n\n**Output**: Respond with JSON conforming to the provided schema - no prose, no markdown.  If you are unable to respond with JSON alone, make sure the text includes tables or fragments of schema compliant that unambiguously capture the elements and their associations that would be captured if returning JSON schema.\n\n```json\n{\n    \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n    \"title\": \"Gene Program Functional Analysis\",\n    \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts. Perform systematic analysis to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states. For each program, predict functional implications for the specified cell type in the context of the provided disease and tissue environment. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant. Rank predictions higher when multiple genes from input list act in same process and when most/all required pathway components are present.\",\n    \"type\": \"object\",\n    \"required\": [\n        \"context\",\n        \"input_genes\",\n        \"programs\",\n        \"version\"\n    ],\n    \"definitions\": {\n        \"atomic_term\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"name\",\n                \"citation\",\n                \"genes\"\n            ],\n            \"properties\": {\n                \"name\": {\n                    \"type\": \"string\",\n                    \"description\": \"A minimal component of the gene program, representing a single biological process or cell component.\"\n                },\n                \"citations\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"$ref\": \"#/definitions/citation\"\n                    },\n                    \"description\": \"list of citations supporting the role of the listed genes in the name biological process or cell component\"\n                },\n                \"genes\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"Genes of the program whose products are involved in this biological process or cell component.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"citation\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"source_id\"\n            ],\n            \"properties\": {\n                \"source_id\": {\n                    \"type\": \"string\"\n                },\n                \"notes\": {\n                    \"type\": \"string\",\n                    \"description\": \"Why this citation supports the claim.\"\n                }\n            },\n            \"additionalProperties\": false\n        }\n    },\n    \"properties\": {\n        \"context\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"cell_type\",\n                \"disease\"\n            ],\n            \"properties\": {\n                \"cell_type\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the name or names of the primary cell type(s) from the provided biological context. Use standard cell type terminology. Leave blank if not specified.\"\n                },\n                \"disease\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the disease or pathological condition from the provided biological context (e.g., 'IDH-mutant astrocytoma', 'Alzheimer disease', 'multiple sclerosis'). Use standard disease terminology. Leave blank if not specified.\"\n                },\n                \"tissue\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the tissue or anatomical location if mentioned in the biological context (e.g., 'brain', 'cerebral cortex', 'hippocampus'). Leave blank if not specified.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"input_genes\": {\n            \"type\": \"array\",\n            \"items\": {\n                \"type\": \"string\",\n                \"minLength\": 1\n            },\n            \"minItems\": 1,\n            \"uniqueItems\": true\n        },\n        \"programs\": {\n            \"type\": \"array\",\n            \"minItems\": 1,\n            \"items\": {\n                \"type\": \"object\",\n                \"required\": [\n                    \"program_name\",\n                    \"description\",\n                    \"predicted_cellular_impact\",\n                    \"evidence_summary\",\n                    \"significance_score\",\n                    \"citations\",\n                    \"supporting_genes\"\n                ],\n                \"description\": \"A gene program, relevant to the provided context. Avoid programs that group 2 or more loosely related processes\",\n                \"properties\": {\n                    \"program_name\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"Provide a concise, descriptive name for this gene program that captures its primary biological function or pathway. Use 2-5 words maximum.\"\n                    },\n                    \"description\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"A more detailed description of the gene program.\"\n                    },\n                    \"atomic_biological_processes\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic biological process terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"atomic_cellular_components\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic cellular component terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"predicted_cellular_impact\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\",\n                            \"description\": \"Concise bullet-level impacts (e.g., ‘enhanced focal adhesion signaling’)\"\n                        }\n                    },\n                    \"evidence_summary\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1\n                    },\n                    \"significance_score\": {\n                        \"description\": \"A value between 0 and 1 that ranks this gene program by the number of supporting genes, the number of supporting references and relevance to the context.\",\n                        \"type\": \"number\",\n                        \"minimum\": 0.0,\n                        \"maximum\": 1.0\n                    },\n                    \"citations\": {\n                        \"description\": \"Array of citations supporting the role of the listed genes in this gene program.\",\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"$ref\": \"#/definitions/citation\"\n                        }\n                    },\n                    \"supporting_genes\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\"\n                        },\n                        \"uniqueItems\": true\n                    },\n                    \"required_genes_not_in_input\": {\n                        \"description\": \"Genes required for this program that are NOT present in the input genes.\",\n                        \"type\": \"object\",\n                        \"properties\": {\n                            \"genes\": {\n                                \"type\": \"array\",\n                                \"items\": {\n                                    \"type\": \"string\"\n                                }\n                            },\n                            \"citations\": {\n                                \"type\": \"array\",\n                                \"minItems\": 1,\n                                \"items\": {\n                                    \"$ref\": \"#/definitions/citation\"\n                                }\n                            }\n                        }\n                    }\n                },\n                \"additionalProperties\": false\n            }\n        },\n        \"method\": {\n            \"type\": \"object\",\n            \"description\": \"Optional trace of how programs were derived\",\n            \"properties\": {\n                \"clustering_basis\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"e.g., pathway databases, co-citation, PPI, co-expression\"\n                },\n                \"notes\": {\n                    \"type\": \"string\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"version\": {\n            \"type\": \"string\"\n        }\n    },\n    \"additionalProperties\": false\n}\n\n```\n\n## Output\n\n<think>\nThis is a complex query asking me to perform a comprehensive literature analysis of a large gene list (74 genes) in the context of malignant glioblastoma cells. The user wants me to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states - and provide output in JSON format conforming to the provided schema.\n\nLet me first review what I found in the search results provided:\n\nFrom the search results, I have information about:\n1. RUNX2 - promotes malignant progression in glioma [2][4]\n2. HIF-1α - hypoxia-inducible factor pathway in glioma, promotes malignant behaviors [3][5]\n3. COX-2/PGE2 - involved in proliferation, angiogenesis, immunosuppression [12][15]\n4. MET - aberrant MET receptor tyrosine kinase signaling in GBM [16]\n5. Eph/ephrin signaling - EphA2/EphA3 correlate with higher tumor grade and invasiveness [17]\n6. COL5A1 - promotes malignancy through extracellular remodeling [18][21]\n7. TRIB3 - facilitates glioblastoma progression [19]\n8. Caveolin-1 (CAV1) - independent negative prognostic marker [20][23]\n9. Integrins - pathophysiological roles in gliomas [24]\n10. NDRG1 - tumor suppressor in glioma [33]\n11. HO-1 - crosstalk with oxidative stress in tumorigenesis [7]\n12. ANGPTL4 - EGF-induced, promotes anoikis resistance and migration [8]\n13. BNIP3L - autophagy-related, linked to hypoxia [9]\n14. MerTK - promotes invasion and survival [13]\n\n\n15. SPNS2 - downregulation triggers epithelial-mesenchymal transition [25]\n16. Hippo signaling pathway involving YAP/TAZ plays critical role in glioma progression [43][46]\n17. Glycosylation mechanisms, particularly O-linked glycans, contribute to epithelial-mesenchymal transition [44][47]\n18. Extracellular matrix components like LTBP2, ABI3BP, and ABLIM3 demonstrate complex interactions [35][48][49][50][51][52]\n19. Microglia-mediated resistance involves activation of interferon-stimulated genes [37][40]\n20. ERRFI1 exhibits differential regulatory functions in AKT/EGFR signaling pathway [56][59]\n\nI'm systematically organizing input genes into interconnected functional programs that reveal complex cellular mechanisms. These programs capture nuanced interactions across metabolic, signaling, and stress response networks, highlighting intricate molecular dynamics in cellular adaptation and transformation.\n\nThe gene programs span critical cellular processes: metabolic reprogramming, invasion dynamics, signaling cascades, inflammatory responses, and stress management. Each program represents a sophisticated molecular strategy for cellular survival and progression.\n\nKey observations emerge from cross-program interactions, particularly in hypoxia adaptation, cell migration, and stress response pathways. Genes like HMOX1, CAV1, and BNIP3L appear in multiple programs, suggesting their pivotal multifunctional roles in cellular plasticity.\n\nThe programs reveal intricate molecular networks driving cellular transformation, emphasizing how gene interactions transcend traditional single-pathway models. Integrative analysis suggests these genes collectively orchestrate complex cellular behaviors beyond individual gene functions.\n\nEmerging themes include metabolic flexibility, immune modulation, and transcriptional regulation - highlighting the sophisticated molecular strategies underlying cellular adaptation and potential malignant transformation.\n</think>\n\n# Comprehensive Literature Analysis: Gene Programs in Malignant Glioblastoma\n\nBased on systematic analysis of provided search results and established molecular biology literature, I have identified 11 major gene programs active in malignant glioblastoma cells. Due to the JSON-only output requirement with schema compliance, the analysis is structured below:\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"glioblastoma cells\",\n    \"disease\": \"glioblastoma multiforme (GBM)\",\n    \"tissue\": \"brain\"\n  },\n  \"input_genes\": [\n    \"ADAM28\", \"LINC02615\", \"POT1-AS1\", \"MET\", \"HILPDA\", \"LUCAT1\", \"PTGS2\", \"RUNX2\", \"SPNS2\", \"PHLDB2\", \"LINC01705\", \"FAM160A1\", \"ERRFI1\", \"FAT4\", \"TNNI3K\", \"TRIB3\", \"NDRG1\", \"AC051619.5\", \"AC083837.1\", \"PRKCH\", \"PPP1R3C\", \"MGAM\", \"ANGPTL4\", \"COL13A1\", \"CHSY3\", \"AP001528.1\", \"CDON\", \"CAV1\", \"SHISA6\", \"SLC39A14\", \"C21orf62-AS1\", \"HMOX1\", \"BNIP3L\", \"LINC01376\", \"ABI3BP\", \"VLDLR-AS1\", \"OLFM1\", \"LTBP2\", \"AHNAK2\", \"NOX4\", \"AC092944.1\", \"COL5A1\", \"PLAG1\", \"GCNT1\", \"AC099681.1\", \"CFAP61\", \"RPL34-AS1\", \"OSMR-AS1\", \"AMPD3\", \"EHHADH\", \"COL24A1\", \"RNF217-AS1\", \"AP006545.3\", \"EPHA1-AS1\", \"EPHA3\", \"ZNF385B\", \"LINC02340\", \"LVRN\", \"PDE4C\", \"GPC5\", \"RCAN2\", \"EPSTI1\", \"AC008014.1\", \"LINC00240\", \"AL158064.1\", \"AL390957.1\", \"MX2\", \"C4orf47\", \"ABLIM3\", \"ITGB3\", \"SCN9A\", \"C9orf153\", \"SLC6A6\", \"NECTIN3-AS1\", \"CALN1\", \"GRK5\", \"CPEB1\", \"CPA4\", \"UNC5C\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Hypoxia-Driven Angiogenesis\",\n      \"description\": \"HIF-1α-dependent pathway driving vascular endothelial growth factor (VEGF) expression, vessel density increases, and hypoxic adaptation in glioblastoma. This program enables tumor cells to promote neovascularization in response to inadequate oxygen tension, supporting rapid tumor growth despite poor vascularization.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"HIF-1α stabilization and activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Comprehensive review of HIF-1α pathway activation through growth factor signaling in gliomas, including EGFR-mediated PI3K/AKT/mTOR pathway\"\n            },\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Demonstrates HIF-1α overexpression in glioblastoma under both normoxic and hypoxic conditions, with functional evidence that knockdown reduces proliferation and migration\"\n            }\n          ],\n          \"genes\": [\n            \"HILPDA\",\n            \"NOX4\",\n            \"HMOX1\",\n            \"BNIP3L\"\n          ]\n        },\n        {\n          \"name\": \"VEGF-mediated angiogenesis and vascular patterning\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"HIF-1α induces VEGF transcription through HRE binding, increasing gene transcription and vessel density\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"COX-2/PGE2 pathway regulates VEGF expression and triggers increased microvessel density in GBM\"\n            }\n          ],\n          \"genes\": [\n            \"PTGS2\",\n            \"ANGPTL4\",\n            \"GPC5\"\n          ]\n        },\n        {\n          \"name\": \"Autophagy induction under hypoxia\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"HIF-1α activates BNIP3 and BNIP3L, which promote autophagy through Beclin-1-BNIP3-Bcl-2 axis under hypoxic stress\"\n            }\n          ],\n          \"genes\": [\n            \"BNIP3L\",\n            \"TRIB3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Hypoxic microenvironment sensing apparatus\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GBM cells show enhanced HIF-1α expression under hypoxic culture conditions, demonstrating active oxygen-sensing capability\"\n            }\n          ],\n          \"genes\": [\n            \"NOX4\",\n            \"HMOX1\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix vascular niche\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Extracellular matrix components including proteoglycans and glycosaminoglycans compose the vascular-tumor interface\"\n            }\n          ],\n          \"genes\": [\n            \"ANGPTL4\",\n            \"GPC5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Increased expression of pro-angiogenic factors (VEGF, ANGPTL4) promoting microvessel density\",\n        \"Enhanced metabolic adaptation to hypoxic stress through autophagy induction\",\n        \"Survival advantage in tumor core regions with limited oxygen availability\",\n        \"Reduced dependence on vasculature for nutrient supply through metabolic shift\"\n      ],\n      \"evidence_summary\": \"Multiple search results demonstrate that HIF-1α is highly expressed in glioblastoma and constitutes a central hub of hypoxia-responsive signaling. BNIP3L and TRIB3 mediate autophagy induction under hypoxic stress, while PTGS2 and ANGPTL4 drive angiogenesis. HMOX1 and NOX4 contribute to redox adaptation. This program is supported by strong experimental evidence showing that HIF-1α knockdown significantly reduces glioblastoma cell proliferation, migration, and colony formation, particularly under hypoxic conditions.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Foundational review of HIF-1α pathway in gliomas with mechanisms of activation and downstream targets\"\n        },\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Recent 2025 study demonstrating HIF-1α mediated regulation of GBM malignant behaviors with experimental validation\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Detailed analysis of HIF-1α dependent autophagy induction through BNIP3/BNIP3L axis and immune modulation\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Role of COX-2/PGE2 in angiogenesis and immune regulation in GBM tumor microenvironment\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"HILPDA\",\n        \"NOX4\",\n        \"HMOX1\",\n        \"BNIP3L\",\n        \"PTGS2\",\n        \"ANGPTL4\",\n        \"GPC5\",\n        \"TRIB3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"HIF1A\",\n          \"VEGFA\",\n          \"PHD2\",\n          \"VHL\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"PHD and VHL proteins are essential components of HIF-1α degradation machinery; VEGFA is canonical HIF-1α target\"\n          },\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"HIF-1α protein itself is the central regulator though not in input gene list\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Epithelial-Mesenchymal Transition and Invasion\",\n      \"description\": \"Coordinated remodeling of cell-cell adhesion, extracellular matrix composition, and cytoskeletal architecture enabling glioblastoma cells to acquire migratory and invasive capacity. This program involves loss of epithelial markers (E-cadherin, claudins) and gain of mesenchymal markers (N-cadherin, vimentin, MMPs), facilitating tumor cell dissemination and invasion of surrounding brain parenchyma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Extracellular matrix remodeling and collagen crosslinking\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"COL5A1 promotes GBM metastasis through PPRC1-ESM1 axis regulating actin filaments and cytoskeleton remodeling\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Cell surface proteomic landscape identifies COL5A1, LTBP2, and other ECM components as key regulators of GBM progression\"\n            },\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"ECM stiffness modulates cancer cell migration through N-cadherin upregulation and E-cadherin downregulation, with MMP-mediated ECM degradation promoting invasion\"\n            }\n          ],\n          \"genes\": [\n            \"COL5A1\",\n            \"COL13A1\",\n            \"COL24A1\",\n            \"LTBP2\",\n            \"ABI3BP\",\n            \"CHSY3\"\n          ]\n        },\n        {\n          \"name\": \"Loss of cell-cell adhesion and E-cadherin function\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"NDRG1 maintains epithelial phenotype through E-cadherin upregulation; loss of NDRG1 correlates with vimentin/N-cadherin upregulation\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"EMT involves glycosylation changes affecting cell adhesion molecules, particularly reduced sialylation on β4 integrins\"\n            }\n          ],\n          \"genes\": [\n            \"NDRG1\",\n            \"FAT4\",\n            \"GCNT1\"\n          ]\n        },\n        {\n          \"name\": \"Acquisition of migratory and invasive phenotype\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"MerTK promotes GBM cell invasion through regulation of actomyosin contractility via RhoA-ROCK-MLC2 pathway\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Integrin-ECM interactions regulate GBM cell migration, proliferation and differentiation through FAK and AKT signaling\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"NDRG1 directly promotes caveolin-1 degradation; loss of NDRG1 results in caveolin-1 accumulation and enhanced migration/invasion\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB3\",\n            \"ABLIM3\",\n            \"CAV1\",\n            \"EPHA3\",\n            \"SPNS2\"\n          ]\n        },\n        {\n          \"name\": \"Glycosylation of cell surface molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"Glioblastomas overexpress O-linked glycan transferases (GALNT1, GALNT2, GALNT7, GALNT10) accumulating Tn antigen, altering immune cell interactions\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"EMT-associated glycosylation changes include increased O-GlcNAcylation affecting cell adhesion and migration\"\n            }\n          ],\n          \"genes\": [\n            \"GCNT1\",\n            \"CHSY3\",\n            \"MGAM\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Focal adhesions and integrin-ECM interfaces\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Integrin αvβ3 and α5β1 mediate GBM cell-ECM adhesion through FAK, paxillin and p130CAS phosphorylation\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"NDRG1 regulates actin cytoskeleton reorganization and focal adhesion dynamics through caveolin-1 modulation\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB3\",\n            \"FAT4\",\n            \"ABI3BP\",\n            \"ABLIM3\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix protein scaffold\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"COL5A1 maintains unique role in fibrous collagen composition and extracellular matrix remodeling in GBM\"\n            },\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"LTBP2 modulates structural integrity of ECM and targets latent TGF-β complex to cell surface\"\n            }\n          ],\n          \"genes\": [\n            \"COL5A1\",\n            \"COL13A1\",\n            \"COL24A1\",\n            \"LTBP2\",\n            \"CHSY3\"\n          ]\n        },\n        {\n          \"name\": \"Actin-myosin contractile apparatus\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"MerTK-dependent regulation of myosin light chain 2 phosphorylation regulates actomyosin contractility and invasion\"\n            },\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"MicroRNAs regulate actin-myosin dynamics; RhoA and Rac1 activate ROCK and PAK1 affecting cytoskeleton reorganization\"\n            }\n          ],\n          \"genes\": [\n            \"ABLIM3\",\n            \"PRKCH\",\n            \"GRK5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced extracellular matrix degradation through increased MMP secretion\",\n        \"Increased migratory velocity and invasive capacity through actin reorganization\",\n        \"Altered expression of adhesion molecules (reduced E-cadherin, increased N-cadherin)\",\n        \"Enhanced integrin-mediated signaling driving survival and proliferation signals\",\n        \"Immune evasion through altered glycosylation of cell surface molecules\",\n        \"Reduced responsiveness to contact inhibition signals\"\n      ],\n      \"evidence_summary\": \"The epithelial-mesenchymal transition program in GBM involves coordinated downregulation of epithelial markers (mediated by NDRG1 loss) coupled with increased expression of mesenchymal markers and invasion-associated proteins. COL5A1 acts as a master regulator through the PPRC1-ESM1 axis to promote metastasis. LTBP2 and other collagen family members remodel the ECM to increase stiffness and promote invasion. Integrin signaling through ITGB3 and FAT4, combined with altered glycosylation (GCNT1, CHSY3), creates a permissive microenvironment for cell migration. CAV1 and SPNS2 dysregulation further enhance migratory phenotype. This program is strongly supported by multiple experimental studies showing that COL5A1 knockdown reduces migration/invasion, NDRG1 overexpression suppresses EMT markers and metastasis, and integrin inhibition impairs GBM cell invasiveness.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"18\",\n          \"notes\": \"COL5A1 is identified as a novel prognostic target and therapeutic target through the PPRC1-ESM1 axis\"\n        },\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"NDRG1 acts as tumor suppressor by inhibiting EMT and promoting E-cadherin expression\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Comprehensive analysis of integrin pathways in GBM metastasis and chemoresistance\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"ECM stiffness and remodeling drive invasion and metastasis through MMP-mediated degradation\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"O-linked glycan alterations in GBM exploit immune modulation through altered glycocode\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"COL5A1\",\n        \"COL13A1\",\n        \"COL24A1\",\n        \"LTBP2\",\n        \"ABI3BP\",\n        \"CHSY3\",\n        \"NDRG1\",\n        \"FAT4\",\n        \"GCNT1\",\n        \"ITGB3\",\n        \"ABLIM3\",\n        \"CAV1\",\n        \"EPHA3\",\n        \"SPNS2\",\n        \"PRKCH\",\n        \"GRK5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\",\n          \"MMP9\",\n          \"SNAI1\",\n          \"SNAI2\",\n          \"ZEB1\",\n          \"ZEB2\",\n          \"CDH1\",\n          \"CDH2\",\n          \"VIM\",\n          \"TGF-β\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"48\",\n            \"notes\": \"MMPs are essential for ECM degradation; SNAI and ZEB transcription factors are canonical EMT regulators\"\n          },\n          {\n            \"source_id\": \"44\",\n            \"notes\": \"CDH1/CDH2 switching and vimentin upregulation are core EMT markers\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Aberrant Receptor Tyrosine Kinase Signaling\",\n      \"description\": \"Dysregulation of multiple receptor tyrosine kinases (RTKs) including MET, EGFR, and Eph receptors driving constitutive activation of downstream proliferation and survival pathways. These receptors activate PI3K/AKT/mTOR and MAPK/ERK cascades, promoting glioblastoma cell growth, survival, and acquisition of drug resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"MET receptor activation and hepatocyte growth factor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"MET is genetically altered in GBM through focal amplification, chromosomal rearrangements, and exon 14 skipping mutations. MET overexpression contributes to chemotherapy resistance through DNA repair upregulation\"\n            }\n          ],\n          \"genes\": [\n            \"MET\"\n          ]\n        },\n        {\n          \"name\": \"Eph receptor signaling and cell adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"EphA2 and EphA3 are overexpressed in glioblastoma and correlate with higher tumor grade and increased invasiveness. Ephrin-A1 and ephrin-A5 promote receptor internalization and degradation, inhibiting proliferation\"\n            },\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Eph/ephrin signaling regulates cell-cell contact and adhesion, with EphA4 promoting cytoskeletal changes in astrocytes through Rho family GTPase regulation\"\n            }\n          ],\n          \"genes\": [\n            \"EPHA3\",\n            \"EPHA1-AS1\"\n          ]\n        },\n        {\n          \"name\": \"Downstream PI3K/AKT/mTOR cascade activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"RTK activation leads to PI3K pathway activation, increasing HIF-1α by PI3K/AKT/FRAP/mTOR pathway. Inhibition with LY294002 and rapamycin reduces HIF-1α\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Integrin αvβ3 activation through cilengitide inhibition demonstrates importance of FAK and AKT signaling in GSC survival and proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"PRKCH\",\n            \"GRK5\",\n            \"ERRFI1\"\n          ]\n        },\n        {\n          \"name\": \"MAPK/ERK pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Phosphorylated p38 and ERK1/2 can phosphorylate and activate HIF-1α downstream of RTK signaling\"\n            },\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"ERRFI1 has differential roles: in EGFR-high cells it negatively regulates EGFR, while in EGFR-low cells it positively modulates AKT signaling\"\n            }\n          ],\n          \"genes\": [\n            \"ERRFI1\",\n            \"GRK5\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Plasma membrane receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"MET RTK undergoes gene amplification and chromosomal rearrangement in GBM, maintaining constitutive receptor signaling\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"EphA receptors form bidirectional signaling complexes with ephrin ligands on adjacent cells\"\n            }\n          ],\n          \"genes\": [\n            \"MET\",\n            \"EPHA3\",\n            \"EPHA1-AS1\"\n          ]\n        },\n        {\n          \"name\": \"Intracellular signaling transducers\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"ERRFI1 interacts with PHLPP and AKT to regulate AKT phosphorylation status and downstream signaling\"\n            }\n          ],\n          \"genes\": [\n            \"PRKCH\",\n            \"GRK5\",\n            \"ERRFI1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Constitutive activation of survival and proliferation signals\",\n        \"Enhanced chemotherapy and radiotherapy resistance through DNA repair pathway activation\",\n        \"Increased glucose uptake and metabolic reprogramming\",\n        \"Promotion of glioma stem cell self-renewal and maintenance\",\n        \"Enhanced invasive capacity through EMT-associated pathways\",\n        \"Reduced dependence on growth factor availability\"\n      ],\n      \"evidence_summary\": \"MET receptor dysregulation is a major driver of GBM progression and chemotherapy resistance, with multiple genetic alteration mechanisms (amplification, fusion, exon 14 skipping). EphA2/A3 overexpression is strongly correlated with glioblastoma grade and invasiveness. These RTKs activate canonical proliferation pathways (PI3K/AKT/mTOR and MAPK/ERK) that drive tumor growth and survival. ERRFI1 shows context-dependent regulation of these cascades. The convergence of multiple RTK pathways in GBM creates redundancy for survival signaling and contributes to therapeutic resistance.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"16\",\n          \"notes\": \"Recent 2024 comprehensive review of MET receptor dysregulation in GBM with targeted therapy strategies\"\n        },\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"2025 review of Eph/ephrin signaling in CNS tumors, identifying EphA2/A3 as key therapeutic targets\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Detailed mechanism of RTK-mediated HIF-1α stabilization through PI3K/AKT/mTOR pathway\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"ERRFI1 differential regulation of EGFR and AKT pathways based on receptor expression level\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"MET\",\n        \"EPHA3\",\n        \"EPHA1-AS1\",\n        \"PRKCH\",\n        \"GRK5\",\n        \"ERRFI1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EGFR\",\n          \"PDGFRA\",\n          \"PI3K\",\n          \"AKT\",\n          \"mTOR\",\n          \"ERK1/2\",\n          \"SOS1\",\n          \"GAB1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"EGFR, PI3K, AKT, and mTOR are core components of RTK-downstream signaling cascades\"\n          },\n          {\n            \"source_id\": \"16\",\n            \"notes\": \"SOS1 and GAB1 are adaptor proteins essential for complete RTK signal transduction\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Inflammatory Signaling and Immune Evasion\",\n      \"description\": \"Coordinated upregulation of cyclooxygenase-2 and prostaglandin E2 signaling coupled with exploitation of altered glycosylation patterns to evade immune surveillance. This program enables glioblastoma cells to create an immunosuppressive tumor microenvironment by recruiting and polarizing immune cells toward protumorigenic phenotypes.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"COX-2/PGE2 axis-driven inflammation\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"COX-2 expression in glioblastomas correlates with aggressive disease aspects: proliferation rate, glioma grade, and poor prognosis. PGE2 is predominant COX-2 product facilitating tumor activities\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Enhanced COX-2/PGE2 signaling leads to pleiotropic effects on GAM dynamics, tumor proliferation, angiogenesis, and immunosuppression. PGE2 is highly enriched in GBM-TME\"\n            }\n          ],\n          \"genes\": [\n            \"PTGS2\"\n          ]\n        },\n        {\n          \"name\": \"Prostaglandin-mediated immune cell recruitment and polarization\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"PGE2 in TME links to increased glioma-derived monocyte chemoattractant CCL2/MCP-1, leading to active GAM recruitment. GAMs then induce IL-6 production increasing GBM invasiveness\"\n            },\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"PGE2 induces immunosuppressive cytokines (IL-6, IL-10, GM-CSF) and blocks T cell infiltration and proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"PTGS2\",\n            \"HMOX1\"\n          ]\n        },\n        {\n          \"name\": \"Glycan-mediated immune modulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"Glioblastomas accumulate Tn antigen through GALNT1/2/7/10 upregulation. Overexpression of truncated O-linked glycans increases PD-L1+ macrophage infiltration and immune suppression\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"EMT-associated glycosylation changes affect immune recognition. Altered O-GlcNAcylation impacts immune synapse formation\"\n            }\n          ],\n          \"genes\": [\n            \"GCNT1\",\n            \"CHSY3\"\n          ]\n        },\n        {\n          \"name\": \"Antigen presentation suppression\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Elevated PGE2 downregulates MHC class II in microglia, responsible for antigen presentation. In GBM patients, MHC class II is downregulated in GAMs leading to ineffective T-cell activation\"\n            },\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Microglia induce interferon-stimulated gene expression profile in glioblastoma cells through STAT1 signaling, enhancing TMZ resistance\"\n            }\n          ],\n          \"genes\": [\n            \"PTGS2\",\n            \"HMOX1\",\n            \"MX2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Prostaglandin signaling receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"PGE2 acts through EP receptor family members to promote tumor progression\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"EP4 receptor-dependent activation of MAPK signaling by PGE2-derived signals\"\n            }\n          ],\n          \"genes\": [\n            \"PTGS2\",\n            \"PDE4C\"\n          ]\n        },\n        {\n          \"name\": \"Glycan biosynthetic machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"GALNT enzymes catalyze initial GalNAc transfer to proteins; GCNT enzymes participate in O-glycan elongation\"\n            }\n          ],\n          \"genes\": [\n            \"GCNT1\",\n            \"CHSY3\"\n          ]\n        },\n        {\n          \"name\": \"Oxidative stress response organelles\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"HO-1 regulates redox homeostasis and transcriptional activity of AP-1, AP-2, and Brn-3 factors; nuclear HO-1 associated with cancer progression and chemotherapeutic resistance\"\n            }\n          ],\n          \"genes\": [\n            \"HMOX1\",\n            \"NOX4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Robust production of immunosuppressive mediators (IL-6, IL-10, GM-CSF)\",\n        \"Preferential recruitment of protumorigenic macrophages and myeloid-derived suppressor cells\",\n        \"Downregulation of MHC class II reducing T-cell activation capacity\",\n        \"Enhanced tumor cell survival against immune attack through altered glycocode recognition\",\n        \"Induction of regulatory T cells further dampening antitumor immunity\",\n        \"Increased resistance to immune checkpoint inhibitor therapy\"\n      ],\n      \"evidence_summary\": \"The inflammatory program in GBM is characterized by high COX-2 expression and elevated PGE2 production, which drives recruitment of immune-suppressive myeloid cells and induces immunosuppressive cytokine production. PGE2 directly downregulates antigen presentation through MHC class II reduction, impeding T cell activation. Additionally, glioblastomas reprogram glycosylation machinery to accumulate Tn antigen, which preferentially recruits PD-L1+ macrophages. HO-1 upregulation provides additional immune evasion through redox regulation. This program is strongly supported by clinical evidence showing that COX-2 expression correlates with poor prognosis and shorter time to radiological recurrence, and that combined COX-2 inhibition with conventional therapy represents a promising strategy.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"Comprehensive review of COX-2 in GBM proliferation, apoptosis, invasion, angiogenesis, and immunosuppression\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Detailed analysis of COX-2/PGE2 pleotropic effects on glioma-associated microglia dynamics and tumor progression\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"Evidence that glioblastomas exploit truncated O-linked glycans for immune evasion through MGL-L ligand accumulation\"\n        },\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Microglia-induced interferon-stimulated genes mediate chemotherapy resistance through STAT1 signaling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PTGS2\",\n        \"HMOX1\",\n        \"NOX4\",\n        \"GCNT1\",\n        \"CHSY3\",\n        \"MX2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PGE2\",\n          \"EP2\",\n          \"EP4\",\n          \"CCL2\",\n          \"IL6\",\n          \"IL10\",\n          \"STAT3\",\n          \"NF-κB\",\n          \"PD-L1\",\n          \"GALNT1\",\n          \"GALNT2\",\n          \"GALNT7\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"12\",\n            \"notes\": \"EP2/EP4, NF-κB, and STAT3 are essential downstream effectors of COX-2/PGE2 signaling\"\n          },\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"GALNT1/2/7 are core enzymes for Tn antigen synthesis; PD-L1 is immune checkpoint target affected by glycosylation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Autophagy and Cellular Stress Response\",\n      \"description\": \"Activation of macroautophagy and selective autophagy pathways in response to metabolic stress, hypoxia, and endoplasmic reticulum stress. This program enables glioblastoma cells to maintain survival under nutrient-poor conditions, contributes to therapy resistance, and regulates immune cell infiltration.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"HIF-1α dependent autophagy initiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Hypoxia-induced autophagy through HIF-1α upregulation of BNIP3 and BNIP3L, rendering Beclin-1 free to promote VPS34 interaction and autophagolysosomes formation\"\n            }\n          ],\n          \"genes\": [\n            \"BNIP3L\",\n            \"TRIB3\"\n          ]\n        },\n        {\n          \"name\": \"TRIB3-mediated autophagy inhibition restraint\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"TRIB3 is known as regulator of cellular responses to stresses such as glucose insufficiency and endoplasmic reticulum stress, facilitating glioblastoma progression\"\n            }\n          ],\n          \"genes\": [\n            \"TRIB3\"\n          ]\n        },\n        {\n          \"name\": \"Metabolic adaptation through protein degradation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Hypoxia-induced autophagy suppresses NK and CTL-mediated tumor degradation by degrading SQSTM1/p62 and Granzyme B\"\n            }\n          ],\n          \"genes\": [\n            \"BNIP3L\",\n            \"TRIB3\",\n            \"AMPD3\"\n          ]\n        },\n        {\n          \"name\": \"Endoplasmic reticulum stress-induced autophagy\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"TRIB3 regulates cellular responses to ER stress through various signaling pathways\"\n            }\n          ],\n          \"genes\": [\n            \"TRIB3\",\n            \"HMOX1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Autophagosomes and autophagolysosomes\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"BNIP3L-Beclin-1 interaction promotes formation of autophagolysosomes for protein degradation\"\n            }\n          ],\n          \"genes\": [\n            \"BNIP3L\",\n            \"TRIB3\"\n          ]\n        },\n        {\n          \"name\": \"Endoplasmic reticulum stress sensors\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"TRIB3 and HMOX1 respond to ER stress signals\"\n            }\n          ],\n          \"genes\": [\n            \"TRIB3\",\n            \"HMOX1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced survival under nutrient deprivation through selective protein degradation\",\n        \"Increased resistance to hypoxic stress through metabolic reprogramming\",\n        \"Enhanced chemotherapy and radiotherapy resistance through autophagy-mediated survival\",\n        \"Suppression of anti-tumor immune responses through autophagy-mediated degradation of immune effector molecules\",\n        \"Maintenance of glioma stem cell phenotype through selective autophagy\",\n        \"Metabolic adaptability enabling rapid response to microenvironmental changes\"\n      ],\n      \"evidence_summary\": \"The autophagy program in GBM is predominantly driven by HIF-1α-dependent induction of BNIP3L and BNIP3, which activate the Beclin-1-VPS34-BNIP3-Bcl-2 axis under hypoxic stress. TRIB3 facilitates progression through regulation of ER stress responses. Multiple mechanistic studies demonstrate that high autophagy turnover tumors are less sensitive to treatments compared with low autophagy turnover tumors. Hypoxia-mediated autophagy induces more resistance than normoxic autophagy, suggesting a dual synergic treatment approach with autophagy inhibitors. The program also involves immune evasion through autophagy-mediated degradation of NK-derived Granzyme B and CTL-derived factors.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Comprehensive review of hypoxia-associated pathways including autophagy induction and immune suppression\"\n        },\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"TRIB3 identified as facilitator of GBM progression through autophagy regulation\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Cilengitide-induced autophagy reduces GBM cell survival and enhances radiosensitivity\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"BNIP3L\",\n        \"TRIB3\",\n        \"HMOX1\",\n        \"AMPD3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"BECN1\",\n          \"ATG7\",\n          \"ATG5\",\n          \"VPS34\",\n          \"BCL2\",\n          \"SQSTM1\",\n          \"DDIT3\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"BECN1, ATG proteins, and VPS34 are core autophagy machinery components\"\n          },\n          {\n            \"source_id\": \"24\",\n            \"notes\": \"SQSTM1 and BCL2 are essential for selective autophagy substrate recognition\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Integrin-Mediated Cell Adhesion and Survival\",\n      \"description\": \"Dysregulated integrin-extracellular matrix interactions promoting cell survival, proliferation, and drug resistance through activation of focal adhesion kinase and associated survival pathways. Integrin αvβ3 and α5β1 are particularly important in glioblastoma, mediating interactions with vitronectin, fibronectin, and other matrix proteins.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Integrin αvβ3 and α5β1 ligand binding and signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Integrin αvβ3 binding to vitronectin and RGD peptides activates downstream FAK, p130CAS, and BMX signaling. Cilengitide, an αvβ3 inhibitor, induces autophagy and reduces GSC survival\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"Integrin αvβ3 is therapeutically targetable fundamental factor in GBM; cilengitide impairs tumorigenesis by hampering angiogenesis, proliferation, and invasion\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB3\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion kinase and downstream signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"FAK and p130CAS phosphorylation downstream of integrin signaling promotes GSC proliferation and survival through AKT activation\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB3\",\n            \"FAT4\",\n            \"ABLIM3\"\n          ]\n        },\n        {\n          \"name\": \"Anoikis resistance and anchorage-independent survival\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"ANGPTL4 confers anoikis resistance to tumor cells by stimulating integrin-dependent survival signals through NADPH oxidase 1 (Nox1) activation, mimicking anchorage conditions\"\n            }\n          ],\n          \"genes\": [\n            \"ANGPTL4\",\n            \"ITGB3\"\n          ]\n        },\n        {\n          \"name\": \"Cilengitide-sensitive autophagy induction\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Cilengitide inhibits GSC self-renewal by inducing autophagy marked by GFP-LC3 spots and increased LC3II expression and autophagic vacuole formation\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB3\",\n            \"BNIP3L\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Integrin heterodimers on cell surface\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Integrin αvβ3 and α5β1 heterodimers serve as primary ECM ligand receptors in GBM\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB3\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"FAK, paxillin, and p130CAS form focal adhesion complexes activated by integrin signaling\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"NDRG1 regulates focal adhesion dynamics and stability through caveolin-1 modulation\"\n          ]\n          \"genes\": [\n            \"ITGB3\",\n            \"FAT4\",\n            \"ABLIM3\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix protein ligands\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Fibronectin, vitronectin, periostin, and collagen serve as integrin ligands in GBM microenvironment\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Vitronectin (VTN) emerged as highest-ranking ECM component in adult glioblastoma cell surface proteomics\"\n            }\n          ],\n          \"genes\": [\n            \"COL5A1\",\n            \"COL13A1\",\n            \"COL24A1\",\n            \"LTBP2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced GSC maintenance and self-renewal through focal adhesion signaling\",\n        \"Increased chemotherapy resistance through anchorage-independent survival signals\",\n        \"Reduced sensitivity to cell detachment-induced apoptosis (anoikis)\",\n        \"Enhanced migration and invasion through integrin-mediated adhesion\",\n        \"Metabolic reprogramming through integrin-AKT signaling\",\n        \"Promotion of GSC differentiation or stemness maintenance depending on matrix composition\"\n      ],\n      \"evidence_summary\": \"Integrin-mediated adhesion signaling is essential for glioblastoma stem cell maintenance and chemotherapy resistance. ITGB3 (integrin β3) forms functional αvβ3 heterodimers that bind ECM ligands including vitronectin and fibronectin, activating FAK and downstream survival pathways. ANGPTL4 enhances integrin-mediated survival through Nox1 activation and NADPH oxidase signaling. FAT4 and ABLIM3 regulate focal adhesion dynamics and actin cytoskeleton organization. The ECM is enriched with multiple collagen species and LTBP2, providing abundant ligands for integrin engagement. Cilengitide, an αvβ3 antagonist, demonstrates therapeutic efficacy by disrupting these survival signals and inducing autophagy.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Comprehensive review of integrin roles in GBM metastasis and chemoresistance\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"ANGPTL4 promotes anoikis resistance and invasion through integrin β1 signaling and MMP-1 upregulation\"\n        },\n        {\n          \"source_id\": \"29\",\n          \"notes\": \"Integrin αvβ3 is therapeutically targetable through cilengitide\"\n        },\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"Vitronectin is highly expressed ECM component in adult GBM\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ITGB3\",\n        \"FAT4\",\n        \"ABLIM3\",\n        \"ANGPTL4\",\n        \"COL5A1\",\n        \"COL13A1\",\n        \"COL24A1\",\n        \"LTBP2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ITGA5\",\n          \"ITGAV\",\n          \"FAK\",\n          \"SRC\",\n          \"PAX\",\n          \"PXN\",\n          \"ITGA6\",\n          \"POSTN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"24\",\n            \"notes\": \"ITGA5 and ITGAV combine with ITGB3/ITGB1 to form functional integrins; FAK, SRC, and adaptor proteins essential for adhesion signaling\"\n          },\n          {\n            \"source_id\": \"24\",\n            \"notes\": \"POSTN ligand binds integrin αvβ3 and inhibits cilengitide cytotoxic effects on GSCs\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Enzyme Dysregulation\",\n      \"description\": \"Altered expression of glycolytic, lipid metabolic, and amino acid metabolic enzymes supporting rapid tumor growth and adaptation to hypoxic and nutrient-poor conditions. Dysregulation includes increased glucose transporter expression, glycogen accumulation pathways, and enhanced fatty acid oxidation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Carbohydrate metabolism and glycogen accumulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Metabolic shift toward carbohydrate metabolism is associated with VEGF blockade adaptation and restriction of lipid synthesis controlling distal metastasis after antiangiogenic treatment\"\n            }\n          ],\n          \"genes\": [\n            \"MGAM\",\n            \"PPP1R3C\"\n          ]\n        },\n        {\n          \"name\": \"Fatty acid oxidation\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Fatty acid oxidation (FAO) favors malignant cell proliferation and impacts survival via drug resistance. Abnormal fatty acid β-oxidation is frequent feature of metabolic reprogramming\"\n            }\n          ],\n          \"genes\": [\n            \"EHHADH\",\n            \"SLC39A14\"\n          ]\n        },\n        {\n          \"name\": \"Amino acid transport and metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Glut-3 (glucose transporter 3) addiction is feature of GSCs; SLC transporters mediate amino acid uptake\"\n            }\n          ],\n          \"genes\": [\n            \"SLC39A14\",\n            \"SLC6A6\"\n          ]\n        },\n        {\n          \"name\": \"Purine/nucleotide metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Hypoxia-adenosine-adenosine receptor axis modulated through HIF-1α-dependent inhibition of adenosine kinase activity, maximizing extracellular adenosine accumulation and depleting ATP\"\n            }\n          ],\n          \"genes\": [\n            \"AMPD3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Glycolytic and glycogenolytic enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Metabolic reprogramming involves upregulation of carbohydrate metabolic pathways\"\n            }\n          ],\n          \"genes\": [\n            \"MGAM\",\n            \"PPP1R3C\"\n          ]\n        },\n        {\n          \"name\": \"Beta-oxidation pathway enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Fatty acids decomposed through β-oxidation to produce acetyl-CoA for Krebs cycle and ATP production\"\n            }\n          ],\n          \"genes\": [\n            \"EHHADH\"\n          ]\n        },\n        {\n          \"name\": \"Nutrient transporters\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"SLC family transporters mediate glucose and amino acid uptake\"\n            }\n          ],\n          \"genes\": [\n            \"SLC39A14\",\n            \"SLC6A6\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced energy production through multiple metabolic pathways (glycolysis, fatty acid oxidation, glutaminolysis)\",\n        \"Rapid adaptation to hypoxic conditions through metabolic switching\",\n        \"Reduced sensitivity to metabolic pathway inhibitors through metabolic redundancy\",\n        \"Increased nucleotide production supporting rapid proliferation\",\n        \"Enhanced survival under nutrient-poor conditions through alternative metabolic routes\",\n        \"Adaptation to antiangiogenic therapy through metabolic reprogramming\"\n      ],\n      \"evidence_summary\": \"Glioblastoma cells demonstrate extensive metabolic reprogramming with dysregulation of multiple carbohydrate and lipid metabolic enzymes. PPP1R3C promotes glycogen accumulation, while MGAM regulates glycan metabolism. EHHADH supports fatty acid β-oxidation contributing to NADPH and acetyl-CoA production. SLC39A14 and SLC6A6 facilitate nutrient uptake. AMPD3 regulates purine metabolism affecting ATP and adenosine levels, which modulates immune cell function. The FAO pathway shows context-dependent prognostic value, with low FAO scores associated with better outcomes in some cancers but differential effects in others, suggesting tumor subtype-specific metabolic dependencies.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Analysis of fatty acid oxidation-related subtypes in cancer showing metabolic shifts and therapy resistance\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"HIF-1α modulation of adenosine metabolism affecting immune cell function and tumor progression\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Glut-3 addiction in GSCs as metabolic vulnerability\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"MGAM\",\n        \"PPP1R3C\",\n        \"EHHADH\",\n        \"SLC39A14\",\n        \"SLC6A6\",\n        \"AMPD3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GLUT1\",\n          \"GLUT3\",\n          \"LDHA\",\n          \"PKM2\",\n          \"HK2\",\n          \"PFKFB3\",\n          \"CPT1A\",\n          \"ACOX1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"GLUT1/GLUT3, LDHA, and PKM2 are canonical glycolytic enzymes overexpressed in GBM\"\n          },\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"CPT1A enables fatty acid entry into mitochondria; ACOX1 participates in peroxisomal fatty acid oxidation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Long Non-Coding RNA Regulatory Networks\",\n      \"description\": \"Dysregulation of multiple long non-coding RNAs that regulate glioblastoma cell proliferation, invasion, drug resistance, and stem cell maintenance. These lncRNAs function as competing endogenous RNAs, scaffold proteins, and transcriptional regulators modulating key oncogenic pathways.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"LUCAT1-mediated RAS pathway promotion\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Long non-coding RNA LUCAT1 regulates RAS pathway to promote proliferation and invasion of malignant glioma cells through ABCB1\"\n            },\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"LUCAT1 promotes GSC self-renewal and GBM tumor growth; identified as potential therapeutic target\"\n            }\n          ],\n          \"genes\": [\n            \"LUCAT1\"\n          ]\n        },\n        {\n          \"name\": \"lncRNA-mediated competing endogenous RNA networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"lncRNAs like LUCAT1 act as competing endogenous RNAs regulating microRNA targeting of mRNAs\"\n            }\n          ],\n          \"genes\": [\n            \"LUCAT1\",\n            \"LINC02615\",\n            \"POT1-AS1\",\n            \"LINC01705\"\n          ]\n        },\n        {\n          \"name\": \"lncRNA-mediated transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"LUCAT1 regulates transcriptional programs supporting glioma stem cell biology\"\n            }\n          ],\n          \"genes\": [\n            \"LUCAT1\",\n            \"LINC01376\",\n            \"LINC00240\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Nuclear ribonucleoprotein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"lncRNAs associate with chromatin-modifying and transcriptional regulatory proteins\"\n            }\n          ],\n          \"genes\": [\n            \"LUCAT1\",\n            \"LINC02615\",\n            \"POT1-AS1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced RAS pathway signaling driving proliferation and invasion\",\n        \"Dysregulated microRNA function through competing endogenous RNA networks\",\n        \"Altered transcriptional landscape supporting GSC maintenance\",\n        \"Enhanced drug resistance through regulation of ABC transporters\",\n        \"Promotion of epithelial-mesenchymal transition phenotypes\",\n        \"Increased tumor aggressiveness and invasion capacity\"\n      ],\n      \"evidence_summary\": \"Long non-coding RNAs comprise an emerging layer of GBM regulatory control. LUCAT1 is particularly well-characterized as promoting GSC self-renewal and GBM tumor growth through RAS pathway activation and ABCB1-mediated drug resistance. Multiple other lncRNAs (LINC02615, POT1-AS1, LINC01705, LINC01376, LINC00240) are dysregulated in malignancy but lack specific functional characterization in the provided literature. LUCAT1 demonstrates therapeutic potential as a target, suggesting broader opportunities for lncRNA-directed therapeutics in GBM.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"LUCAT1 regulates RAS pathway and ABCB1-mediated drug resistance in malignant glioma\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"LUCAT1 promotes GSC self-renewal and identified as therapeutic target in GBM\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"LUCAT1\",\n        \"LINC02615\",\n        \"POT1-AS1\",\n        \"LINC01705\",\n        \"LINC01376\",\n        \"LINC00240\",\n        \"AC051619.5\",\n        \"AC083837.1\",\n        \"AC092944.1\",\n        \"AC008014.1\",\n        \"AL158064.1\",\n        \"AL390957.1\",\n        \"AC099681.1\",\n        \"VLDLR-AS1\",\n        \"EPHA1-AS1\",\n        \"NECTIN3-AS1\",\n        \"RPL34-AS1\",\n        \"OSMR-AS1\",\n        \"RNF217-AS1\",\n        \"AP006545.3\",\n        \"AP001528.1\",\n        \"LINC02340\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"let-7\",\n          \"miR-29\",\n          \"miR-34\",\n          \"DROSHA\",\n          \"DICER1\",\n          \"AGO2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"39\",\n            \"notes\": \"microRNAs regulated by lncRNAs through competing endogenous RNA mechanism\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Control of Differentiation and Stemness\",\n      \"description\": \"Dysregulation of transcription factors and co-regulators controlling glioblastoma stem cell maintenance versus differentiation transitions. RUNX2 drives malignant progression through increased proliferation and expression of invasion-associated genes, while NDRG1 acts as a metastasis suppressor maintaining differentiated epithelial phenotype.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"RUNX2-mediated malignant progression\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"RUNX2 is highly expressed in GBM tissues compared to normal brain and low-grade gliomas. RUNX2 protein level positively correlates with GBM cell proliferative capacity\"\n            },\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Stable transduction of dominant-negative Runx2 inhibits promoter activity and decreases Mmp13 and Spp1 expression, reducing proliferative capacity\"\n            },\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Cross-talk between cAMP/PKA signaling and RUNX2 promotes malignant phenotype through Ccnd1 expression\"\n            }\n          ],\n          \"genes\": [\n            \"RUNX2\"\n          ]\n        },\n        {\n          \"name\": \"NDRG1-mediated tumor suppression and differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"NDRG1 expression positively correlates with longer survival in GBM patients. Decreased NDRG1 correlates with higher WHO grade and poor prognosis\"\n            },\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"NDRG1 overexpression inhibits cell proliferation and invasion, suppresses tumorigenesis in mouse model. NDRG1 facilitates adherent junction formation and E-cadherin positive correlation\"\n            },\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"NDRG1 regulates EMT through modulation of vimentin, N-cadherin, and E-cadherin expression\"\n            }\n          ],\n          \"genes\": [\n            \"NDRG1\"\n          ]\n        },\n        {\n          \"name\": \"RCAN2 regulation of calcineurin-NFAT signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"RCAN2 (regulator of calcineurin-2) inhibits calcineurin and influences calcineurin-NFAT signaling affecting differentiation and proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"RCAN2\"\n          ]\n        },\n        {\n          \"name\": \"ERRFI1 context-dependent regulation of growth\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"ERRFI1 has dual function: in EGFR-high cells it inhibits growth, while in EGFR-low cells it promotes growth by positive regulation of AKT\"\n            },\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"ERRFI1 induces apoptosis in hepatocellular carcinoma, functions as tumor suppressor through PDCD2 interaction\"\n            }\n          ],\n          \"genes\": [\n            \"ERRFI1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factor protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"RUNX2 binds to DNA through RUNX2 response elements to activate target genes\"\n            }\n          ],\n          \"genes\": [\n            \"RUNX2\",\n            \"RCAN2\",\n            \"ERRFI1\"\n          ]\n        },\n        {\n          \"name\": \"Cell adhesion molecule complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"NDRG1 protein-bound to adherent junctions, regulates E-cadherin mediated adhesion\"\n            }\n          ],\n          \"genes\": [\n            \"NDRG1\",\n            \"FAT4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"RUNX2-driven increase in proliferative capacity and expression of invasion-associated MMPs\",\n        \"NDRG1 loss associated with EMT transition, increased invasiveness, and poor prognosis\",\n        \"RCAN2-mediated effects on differentiation through calcineurin-NFAT axis\",\n        \"Context-dependent growth effects of ERRFI1 based on EGFR expression level\",\n        \"Dysregulation of cell cycle checkpoint control\",\n        \"Altered response to differentiation signals\"\n      ],\n      \"evidence_summary\": \"Glioblastoma exhibits marked dysregulation of transcriptional control genes. RUNX2 is significantly upregulated and promotes malignant progression through increased proliferation, MMP13/SPP1 expression, and cyclin D1 activation via cAMP/PKA signaling cross-talk. In stark contrast, NDRG1 acts as a potent tumor suppressor whose loss correlates with poor prognosis and is associated with increased WHO grade. NDRG1 maintains epithelial differentiation through E-cadherin upregulation and suppresses EMT markers. RCAN2 modulates differentiation through calcineurin-NFAT signaling. ERRFI1 shows context-dependent roles, functioning as tumor suppressor in EGFR-high cells but promoting growth in EGFR-low cells.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"RUNX2 promotes malignant progression in glioma through cross-talk with cAMP/PKA signaling\"\n        },\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"Comprehensive review of NDRG1 as critical regulator of differentiation and invasion in GBM\"\n        },\n        {\n          \"source_id\": \"38\",\n          \"notes\": \"RCAN2 as p53-regulated gene influencing cancer progression through calcineurin signaling\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"ERRFI1 dual mechanism in AKT and EGFR pathway regulation based on receptor expression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"RUNX2\",\n        \"NDRG1\",\n        \"RCAN2\",\n        \"ERRFI1\",\n        \"FAT4\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MYC\",\n          \"CCND1\",\n          \"TP53\",\n          \"PTEN\",\n          \"CDH1\",\n          \"CDH2\",\n          \"ZEB1\",\n          \"SNAI1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"2\",\n            \"notes\": \"CCND1 and MYC are downstream targets of RUNX2 and transcriptional regulators\"\n          },\n          {\n            \"source_id\": \"33\",\n            \"notes\": \"TP53 mutations affect NDRG1 regulation; EMT transcription factors ZEB1, SNAI1 are NDRG1 targets\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Redox Homeostasis and Oxidative Stress Response\",\n      \"description\": \"Dysregulation of antioxidant defense systems and oxidative stress sensors affecting tumor progression, drug resistance, and immune evasion. HO-1 and NOX4 represent dual-faced regulators that maintain cellular redox balance while promoting cancer progression through complex, context-dependent mechanisms.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"HO-1 mediated cytoprotection and apoptosis resistance\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"HO-1 is expressed in broad range of cancer types including glioblastoma. Both full-length HO-1 and truncated HO-1 prevent cell death under oxidative stress by H2O2 induction\"\n            },\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"Nuclear HO-1 translocation associated with malignant progression in head/neck cancers and lung cancers, with nuclear HO-1 promoting tumor growth in squamous cell carcinoma model\"\n            }\n          ],\n          \"genes\": [\n            \"HMOX1\"\n          ]\n        },\n        {\n          \"name\": \"NOX4-derived ROS and metabolic reprogramming\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"NOX4-derived ROS-induced overexpression of FOXM1 leads to cancer development and progression through oxidative stress\"\n            }\n          ],\n          \"genes\": [\n            \"NOX4\"\n          ]\n        },\n        {\n          \"name\": \"ANGPTL4-mediated ROS generation and survival signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"ANGPTL4 stimulates integrin-dependent survival signals through NADPH oxidase 1 (Nox1) activation, mimicking anchorage conditions and conferring anoikis resistance through ROS\"\n            }\n          ],\n          \"genes\": [\n            \"ANGPTL4\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Heme oxygenase-1 enzyme and products\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"HO-1 catalyzes heme catabolism to biliverdin, bilirubin, and carbon monoxide, with heme directly regulating HO-1 expression through BACH1 interaction\"\n            }\n          ],\n          \"genes\": [\n            \"HMOX1\"\n          ]\n        },\n        {\n          \"name\": \"NADPH oxidase complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"NOX4 generates ROS as major component of NADPH oxidase family\"\n            },\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"ANGPTL4 activates Nox1 component of NADPH oxidase complex\"\n            }\n          ],\n          \"genes\": [\n            \"NOX4\",\n            \"ANGPTL4\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cellular survival under oxidative stress conditions\",\n        \"Reduced response to ROS-generating chemotherapy agents\",\n        \"Nuclear HO-1 translocation associated with poor prognosis and therapy resistance\",\n        \"NOX4-derived ROS driving metabolic reprogramming and FOXM1 expression\",\n        \"ANGPTL4-mediated anoikis resistance through ROS-dependent signaling\",\n        \"Altered immune cell function through ROS modulation and adenosine accumulation\"\n      ],\n      \"evidence_summary\": \"Redox homeostasis dysregulation is a hallmark of GBM aggressiveness. HO-1 is consistently upregulated in GBM and exerts cytoprotective effects preventing apoptosis under oxidative stress. Importantly, nuclear translocation of HO-1 (distinct from cytoplasmic localization) correlates with cancer progression and poor prognosis, suggesting context-dependent roles. NOX4-derived ROS drives aerobic glycolysis and metabolic reprogramming through FOXM1 upregulation. ANGPTL4 leverages ROS generation through Nox1 activation to confer anoikis resistance and promote invasion. This program demonstrates the paradox where cancer cells simultaneously require antioxidant defenses while exploiting controlled ROS generation for survival and progression signals.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"Comprehensive review of HO-1 role in tumorigenesis with dual pro- and anti-survival functions\"\n        },\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"NOX4-derived ROS in cancer development and progression\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"ANGPTL4-mediated ROS generation through Nox1 activation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"HMOX1\",\n        \"NOX4\",\n        \"ANGPTL4\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOD1\",\n          \"SOD2\",\n          \"CAT\",\n          \"GPX1\",\n          \"NRF2\",\n          \"KEAP1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"7\",\n            \"notes\": \"SOD, CAT, and GPX are canonical antioxidant defense enzymes; NRF2 is master regulator of antioxidant response\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Composition and Immune Targeting\",\n      \"description\": \"Dysregulation of glycosaminoglycan and proteoglycan synthesis enzymes altering extracellular matrix composition to promote immune evasion and support tumor growth. This program involves specific glycosylation modifications that reduce immune recognition while maintaining structural integrity of the tumor microenvironment.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Chondroitin sulfate biosynthesis and deposition\",\n          \"citations\": [\n            {\n              \"source_id\": \"54\",\n              \"notes\": \"Seven chondroitin sulfate biosynthetic enzymes (B4GALT7, B3GALT6, B3GAT3, CHSY3, CHSY1, CHPF, CHPF2) significantly increased in colorectal cancer and correlated with worse prognosis\"\n            }\n          ],\n          \"genes\": [\n            \"CHSY3\"\n          ]\n        },\n        {\n          \"name\": \"O-linked glycan biosynthesis in glioblastoma\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"GALNT1, GALNT2, GALNT7, GALNT10 upregulated in glioblastoma suggesting high Tn antigen score. O-glycan elongation enzymes C1GalT and GCNT2 also increased\"\n            }\n          ],\n          \"genes\": [\n            \"GCNT1\",\n            \"CHSY3\"\n          ]\n        },\n        {\n          \"name\": \"Glycosaminoglycan accumulation and immune suppression\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"Accumulation of (s)Tn-rich glycoproteins on GBM surface increases infiltration of PD-L1+ immune-suppressive macrophages\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"CSPG5 (chondroitin sulfate proteoglycan 5) and other CSPGs identified as cell surface targets in pediatric high-grade gliomas\"\n            }\n          ],\n          \"genes\": [\n            \"GCNT1\",\n            \"CHSY3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Glycosaminoglycan attachment sites\",\n          \"citations\": [\n            {\n              \"source_id\": \"54\",\n              \"notes\": \"Chondroitin sulfate chains attach to core proteins through glycosaminoglycan-protein linkage\"\n            }\n          ],\n          \"genes\": [\n            \"CHSY3\",\n            \"GCNT1\"\n          ]\n        },\n        {\n          \"name\": \"Cell surface glycoprotein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"MUC1 and MUC4 mucins carry Tn antigen; altered GALNT expression reprograms O-glycosylation machinery in GBM\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"CSPG4, CSPG5, GPC2 identified as cell surface ECM-associated targets in gliomas\"\n            }\n          ],\n          \"genes\": [\n            \"GCNT1\",\n            \"CHSY3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered cell surface glycosylation pattern reducing MHC peptide presentation efficiency\",\n        \"Preferential recruitment of immunosuppressive macrophages through glycan-lectin interactions\",\n        \"Decreased recognition by cytotoxic T lymphocytes and NK cells\",\n        \"Enhanced immune checkpoint engagement (PD-L1 interactions)\",\n        \"Maintenance of ECM structural integrity supporting tumor architecture\",\n        \"Protection from complement-mediated lysis\"\n      ],\n      \"evidence_summary\": \"Glioblastomas exploit glycosylation reprogramming as a major immune evasion mechanism. Upregulation of GALNT enzymes leads to accumulation of truncated O-linked glycans, particularly the Tn antigen, on cell surface glycoproteins. GCNT1 and CHSY3 promote synthesis of complex glycan structures. These altered glycans preferentially bind to macrophage galactose-type lectin (MGL), recruiting PD-L1+ immunosuppressive macrophages while simultaneously reducing recognition by immune effector cells. This program is supported by evidence that COSMC knockout (preventing Tn antigen elongation) reduces EMT and increases malignancy in some contexts, while increased Tn antigen score is associated with immune evasion. The glycocode represents both a biomarker and therapeutic target for GBM immunotherapy.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation through MGL targeting\"\n        },\n        {\n          \"source_id\": \"54\",\n          \"notes\": \"Chondroitin sulfate biosynthetic genes correlate with worse prognosis and immune response alterations\"\n        },\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"In-depth cell surface proteomic landscape of HGG ECM identifying glycosylated proteins as immune targets\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"EMT-associated glycosylation changes affecting immune recognition\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GCNT1\",\n        \"CHSY3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GALNT1\",\n          \"GALNT2\",\n          \"GALNT7\",\n          \"GALNT10\",\n          \"C1GALT1C1\",\n          \"MUC1\",\n          \"MUC4\",\n          \"CSPG4\",\n          \"CSPG5\",\n          \"GPC2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"GALNT enzymes are essential for Tn antigen synthesis; COSMC (C1GALT1C1) chaperone enables Tn elongation\"\n          },\n          {\n            \"source_id\": \"35\",\n            \"notes\": \"CSPG4, CSPG5, and GPC2 are direct therapeutic targets identified in HGG ECM proteomic survey\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Literature-based functional annotation from provided search results\",\n      \"Pathway database integration (PI3K/AKT/mTOR, MAPK/ERK, Hippo, Wnt, TGF-β signaling)\",\n      \"Gene ontology enrichment for biological processes and cellular components\",\n      \"Co-expression patterns and shared regulatory mechanisms\",\n      \"Context-specific dysregulation in malignant glioblastoma versus normal neural tissue\"\n    ],\n    \"notes\": \"Analysis prioritized genes with strong direct evidence from search results (RUNX2, HIF-1α pathway genes, COX-2, MET, Eph receptors, COL5A1, NDRG1, CAV1, integrins, autophagy genes, lncRNAs). Genes lacking direct search result evidence were assigned to programs based on established biological functions and pathway relationships. Some genes remain uncharacterized (e.g., FAM160A1, CALN1, CFAP61, C4orf47, SHISA6, UNC5C, OLFM1) due to limited search result data. JSON schema compliance required conversion of narrative clustering approach to structured program definitions.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Supplementary Technical Notes\n\nThe analysis identified 11 major gene programs organized by functional role and pathway involvement:\n\n| Program | Key Characteristics | Evidence Strength |\n|---------|-------------------|------------------|\n| Hypoxia-Driven Angiogenesis | HIF-1α central hub; BNIP3L/TRIB3 autophagy; ANGPTL4 vascular interaction | Very Strong (4+ sources) |\n| EMT and Invasion | COL5A1/LTBP2 ECM remodeling; NDRG1 differentiation suppression; integrin dysregulation | Very Strong (5+ sources) |\n| RTK Signaling | MET amplification; EphA2/A3 overexpression; PI3K/AKT/mTOR cascade | Strong (3+ sources) |\n| Inflammatory Signaling | COX-2/PGE2 axis; immune recruitment and polarization; antigen presentation suppression | Very Strong (4+ sources) |\n| Autophagy Response | HIF-1α→BNIP3L/BNIP3 axis; ER stress responses via TRIB3; immune evasion | Strong (3+ sources) |\n| Integrin Adhesion | αvβ3/α5β1 survival signaling; FAK activation; anoikis resistance via ANGPTL4 | Strong (3+ sources) |\n| Metabolic Enzymes | Glycogen accumulation; fatty acid oxidation; amino acid transport | Moderate (limited direct GBM evidence) |\n| lncRNA Regulation | LUCAT1 RAS pathway promotion and GSC maintenance | Moderate (2 specific sources) |\n| Transcriptional Control | RUNX2 malignancy driver; NDRG1 tumor suppressor; ERRFI1 context-dependent roles | Very Strong (4+ sources) |\n| Redox Homeostasis | HO-1 cytoprotection; NOX4-derived ROS; ANGPTL4-Nox1 signaling | Moderate (distributed across sources) |\n| Glycosylation and Immunity | Tn antigen accumulation; CSPG deposition; immune evasion | Strong (3+ sources) |\n\n**Genes With Limited Literature Support in Provided Search Results** (assigned to programs based on established biological function):\nADAM28, FAM160A1, SHISA6, PLAG1, CFAP61, RPL34-AS1, OSMR-AS1, AP006545.3, EPHA1-AS1, ZNF385B, LINC02340, LVRN, PDE4C (partial), EPSTI1, AC008014.1, AL158064.1, AL390957.1, C4orf47, C9orf153, CALN1, CPEB1, UNC5C, OLFM1, AHNAK2, and numerous AC/AL lncRNA scaffolds.\n\n## Citations\n\n1. https://www.bohrium.com/paper-details/a-time-based-and-intratumoral-proteomic-assessment-of-a-recurrent-glioblastoma-multiforme/811158864945741826-8928\n2. https://pubmed.ncbi.nlm.nih.gov/30203400/\n3. https://pmc.ncbi.nlm.nih.gov/articles/PMC1871894/\n4. https://okayama.elsevierpure.com/en/publications/runx2-promotes-malignant-progression-in-glioma\n5. https://pmc.ncbi.nlm.nih.gov/articles/PMC11705044/\n6. https://www.oncotarget.com/article/22150/text/\n7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8471703/\n8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5415642/\n9. https://pmc.ncbi.nlm.nih.gov/articles/PMC8861358/\n10. https://pmc.ncbi.nlm.nih.gov/articles/PMC8571893/\n11. https://aacrjournals.org/cancerres/article-abstract/79/9/2298/640646\n12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5226867/\n13. https://www.nature.com/articles/onc2012104\n14. https://pmc.ncbi.nlm.nih.gov/articles/PMC6291014/\n15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9909545/\n16. https://pubmed.ncbi.nlm.nih.gov/38334610/\n17. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2025.1658651/full\n18. https://www.nature.com/articles/s41420-021-00661-3\n19. https://pubmed.ncbi.nlm.nih.gov/33203798/\n20. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.701933/full\n21. https://pubmed.ncbi.nlm.nih.gov/34702798/\n22. https://aacrjournals.org/mcr/article/17/5/1102/90037/An-Integrated-Stress-Response-Agent-that-Modulates\n23. https://pmc.ncbi.nlm.nih.gov/articles/PMC10827802/\n24. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.962481/full\n25. https://pmc.ncbi.nlm.nih.gov/articles/PMC8264774/\n26. https://www.ncbi.nlm.nih.gov/gene/3690\n27. https://pmc.ncbi.nlm.nih.gov/articles/PMC500423/\n28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6636018/\n29. https://aacrjournals.org/cancerrescommun/article/3/12/2483/731529/Integrin-v-3-is-a-Therapeutically-Targetable\n30. https://www.nature.com/articles/onc201774\n31. https://jgo.amegroups.org/article/view/83479/html\n32. https://www.repository.unipr.it/bitstream/1889/3549/7/TESI%20DOTTORATO%20Medicina%20Mol%20Elena%20Garusif.pdf\n33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9029626/\n34. https://pubmed.ncbi.nlm.nih.gov/33450224/\n35. https://pmc.ncbi.nlm.nih.gov/articles/PMC12167366/\n36. https://pubmed.ncbi.nlm.nih.gov/36270516/\n37. https://pmc.ncbi.nlm.nih.gov/articles/PMC11618491/\n38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8335924/\n39. https://pubmed.ncbi.nlm.nih.gov/38456228/\n40. https://pmc.ncbi.nlm.nih.gov/articles/PMC8582528/\n41. https://en.wikipedia.org/wiki/RCAN2\n42. https://onlinelibrary.wiley.com/doi/full/10.1002/ccs3.70042\n43. https://pmc.ncbi.nlm.nih.gov/articles/PMC7831924/\n44. https://pmc.ncbi.nlm.nih.gov/articles/PMC8301408/\n45. https://pmc.ncbi.nlm.nih.gov/articles/PMC12381534/\n46. https://www.nature.com/articles/s41392-022-01191-9\n47. https://www.pnas.org/doi/10.1073/pnas.1907921117\n48. https://www.nature.com/articles/s41419-024-06697-4\n49. https://maayanlab.cloud/Harmonizome/gene/ABI3BP\n50. https://pmc.ncbi.nlm.nih.gov/articles/PMC11031727/\n51. https://pmc.ncbi.nlm.nih.gov/articles/PMC5919710/\n52. https://pmc.ncbi.nlm.nih.gov/articles/PMC6426741/\n53. https://pmc.ncbi.nlm.nih.gov/articles/PMC7408560/\n54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8710744/\n55. https://pubmed.ncbi.nlm.nih.gov/25135281/\n56. https://pmc.ncbi.nlm.nih.gov/articles/PMC5835844/\n57. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.763875/epub\n58. https://pubmed.ncbi.nlm.nih.gov/18199537/\n59. https://www.nature.com/articles/s41420-021-00666-y",
    "citations": [],
    "duration_seconds": 216.23
  }
}